G-Magsulph2.5 gm/5 ml

G-Magsulph 2.5 gm/5 ml injection is indicated mainly for the treatment of hypomagnesaemia and magnesium deficiency states. Irregular heart beats, some time it may be used as a laxative. G-Magsulph 2.5 gm/5 ml injection is used in the treatment of magnesium deficiency. G-Magsulph 2.5 gm/5 ml has anticonvulsant properties ... Read moreG-Magsulph 2.5 gm/5 ml injection is indicated mainly for the treatment of hypomagnesaemia and magnesium deficiency states. Irregular heart beats, some time it may be used as a laxative. G-Magsulph 2.5 gm/5 ml injection is used in the treatment of magnesium deficiency. G-Magsulph 2.5 gm/5 ml has anticonvulsant properties when administered parentally, it may be used to prevent or control of Seizures associated with acute uremia, hypothyroidism and eclampsia. It is also used in bronchial asthma & cardiovascular disorder.

Magnesium is an essential constituent of many enzyme systems, particularly those involved in energy generation; the largest stores are in the skeleton. Each 5 ml ampoule of injection contains 50% solution of Magnesium sulphate heptahydrate BP (Mg2+ approx. 2 mmol/ml), total 2.47gm. Each 100 ml bottle of infusion contains 4% solution of Magnesium sulphate heptahydrate BP (Mg2+ approx. 0.16 mmol/ml), total 4 gm.

Specific mineral preparations

Magnesium is the second most plentiful cation of the intracellular fluids. It is essential for the activity of many enzyme systems and plays an important role with regard to neurochemical transmission and muscular excitability. Deficits are accompanied by a variety of structural and functional disturbances.

Intramuscular: Adults and older children: For severe hypomagnesemia, 1 to 5 gm (2 to 10 ml of 50% solution) daily in divided doses; administration is repeated daily until serum levels have returned to normal. If deficiency is not severe, 1 gm (2 ml of 50% solution) can be given once or twice daily. Serum magnesium levels should serve as a guide to continued dosage.Intravenous: 1 to 4 gm G-Magsulph 2.5 gm/5 ml (G-Magsulph 2.5 gm/5 ml (G-Magsulph 2.5 gm/5 ml injection) injection) may be given intravenously in 10% to 20% solution, but only with great caution; the rate should not exceed 1.5 ml of 10% solution or equivalent per minute until relaxation is obtained.Usual Dose Range: 1 to 40 gm daily.Electrolyte Replenisher: Intramuscular 1 to 2 gm in 50% solution four times a day until serum magnesium is within normal limits.Usual Pediatric Dose: Intramuscular 20 to 40 mg per kg of body weight in a 20% solution repeated as necessary.For Eclampsia: Initially 1 to 2 gm in 25% or 50% solution is given intramuscularly. Subsequently, 1 gm is given every 30 minutes until relief is obtained. The blood pressure should be monitored after each injection.

Adult dose- Intramuscular: For severe hypomagnesemia, 1 to 5 g (2 to 10 mL of 50% solution) daily in divided doses; administration is repeated daily until serum levels have returned to normal. If the deficiency is not severe, 1 g (2 ml of 50% solution) can be given once or twice daily. Serum magnesium levels should serve as a guide to continued dosage. Intravenous: 1 to 4 g G-Magsulph 2.5 gm/5 ml injection may be given intravenously in 10% to 20% solution, but only with great caution; the rate should not exceed 1.5 mL of 10% solution or equivalent per minute until relaxation is obtained. Usual Dose Range: 1 to 40 g daily. Electrolyte Replenisher: Intramuscular 1 to 2 g in 50% solution four times a day until serum magnesium is within normal limits. Usual Pediatric Dose- Intramuscular: 20 to 40 mg per kg of body weight in a 20% solution repeated as necessary. For Eclampsia: Initially, 1 to 2 g in 25% or 50% solution is given intramuscularly. Subsequently, 1 g is given every 30 minutes until relief is obtained. The blood pressure should be monitored after each injection. Use in Children & Adolescents: G-Magsulph 2.5 gm/5 ml seems to be beneficial in the treatment of moderate to severe asthma in children as adjuvant therapy.

With medicine: G-Magsulph 2.5 gm/5 ml may cause a reduction in blood pressure when taken together with Calcium channel blockers such as nifedipine. There may be an increase in the effects of neuromuscular blocking agents when given together with G-Magsulph 2.5 gm/5 ml. When G-Magsulph 2.5 gm/5 ml is given together with the following medicines there may be a risk of respiratory depression on high-dose barbiturates, opioids and aminoglycosides antibiotics.With food & others: There is no interaction of G-Magsulph 2.5 gm/5 ml with food & others.

G-Magsulph 2.5 gm/5 ml contra-indicated in the case of a defect of the heart's electrical message pathways resulting in decreased function of the heart (heart block), severe damage to the muscular wall of the heart (myocardium) and significantly decreased kidney function.

Common: Excessive administration of magnesium leads to the development of hypermagnesaemia. Symptoms of hypermagnesaemia may include nausea, vomiting, flushing of skin, thirst, hypotension due to peripheral vasodilatation, drowsiness, confusion, muscle weakness etc.Rare: Diarrhea or skin irritation after soaking may occur.

G-Magsulph 2.5 gm/5 ml crosses the placenta. So, as with any other drugs, caution is required when the drug is administered to pregnant women. It is not known whether the drug is excreted in human milk. As it happens with many other drugs, cautions should be taken when it is administered to a nursing mother.

Magnesium salts should be administered with caution to patients with impaired renal function or those receiving digitalis glycosides. Parenteral administration of magnesium salts may enhance the effect of neuromuscular blocking agents or of central nervous system depressants. Monitor blood pressure, respiratory rate, urinary output and for signs of over dosage like loss of patellar reflex, weakness, nausea, sensation of warmth, flushing of skin, drowsiness, double, vision and slurred speech.

Symptoms of hypermagnesemia are: respiratory depression and loss of deep tendon reflexes due to neuromuscular blockade, nausea, vomiting, flushing, thirst, hypotension, drowsiness, confusion, slurred speech, double vision, bradycardia and muscle weakness.

Store in a cool & dry place, keep away from light & children.

Use in Children & Adolescents: G-Magsulph 2.5 gm/5 ml seems to be beneficial in the treatment of moderate to severe asthma in children as an adjuvant therapy.

Specific mineral preparations

Magnesium is the second most plentiful cation of intracellular fluids. It is essential for the activity of many enzyme systems and plays an important role with regard to neurochemical transmission and muscular excitability. Deficits are accompanied by a variety of structural and functional disturbances.

G-Magsulph 2.5 gm/5 ml crosses the placenta. So, as with any other drugs, caution is required when the drug is administered to pregnant women. It is not known whether the drug is excreted in human milk. As it happens with many other drugs, cautions should be taken when it is administered to a nursing mother.